Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab-Reference-Cited by-同舟云学术

Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab

Published:2020-10-22 Issue:2 Volume:46 Page:306-313
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:Clin Exp Dermatol

Author:

Frew J. W.¹^ORCID,Jiang C. S.²,Singh N.²,Grand D.¹³,Navrazhina K.¹⁴^ORCID,Vaughan R.²,Krueger J. G.¹

Affiliation:

1. Laboratory of Investigative Dermatology The Rockefeller University New York NYUSA

2. Department of Biostatistics The Rockefeller University New York NY USA

3. Albert Einstein College of Medicine Bronx, New York NY USA

4. Weill Cornell/Rockefeller/Sloan Kettering Tri‐Institutional MD‐PhD Program Weill Cornell University New York NY USA

Funder

National Institute of General Medical Sciences

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.14448

Reference18 articles.

1. Hidradenitis Suppurativa

2. Development of a Quality-of-Life Measure for Hidradenitis Suppurativa

3. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

4. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

5. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hidradenitis Suppurativa: New Targets and Emerging Treatments;American Journal of Clinical Dermatology;2024-07-26

2. Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis;Journal of the American Academy of Dermatology;2024-07

3. Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity;Australasian Journal of Dermatology;2024-06-25

4. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial;British Journal of Dermatology;2024-04-05

5. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm;Expert Review of Clinical Immunology;2023-12-22